Contribution of human papillomavirus second-generation hybrid capture test for the diagnosis of cervical pathology in HIV-infected outpatients;Contribución de la captura de híbridos de segunda generación del virus del papiloma humano en el cribado de afección cervical en mujeres con infección por el virus de la inmunodeficiencia humana

Medicina Clinica

Volumn 125, Issue 4, 2005, Pages 127-131

  Sirera, Guillem ^a,b   Videla, Sebastian ^a,b   Castellá, Eva ^a,b   Cavallé, Lluís ^a,b   Grané, Núria ^a,b   Llatjos, Mariona ^a,b   Tural, Cristina ^a,b   Negredo, Eugenia ^a,b   Fernández, Ángela ^a,b   Rey Joly, Celestino ^a,b   Clotet, Bonaventura ^a,b  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Cytology; HIV; Human papillomavirus; Hybrid capture

Indexed keywords

ADULT; ARTICLE; CANCER SCREENING; CARCINOGENICITY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MAJOR CLINICAL STUDY; OUTPATIENT; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; VIRUS INFECTION; WART VIRUS;

EID: 23044498256     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13076944     Document Type: Article

References (41)

1. Walboomers JMM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus types associated with cervical cancer. J Pathol. 1999;189:12-9.
2. Muñoz N, Bosch FX, De Sanjosé S, Herrero R, Castellsagué X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;384:518-27.
3. Bosch FX, De Sanjosé S. Human papillomavirus in cervical cancer. Curr Oncol Rep. 2002;4:175-83.
4. Franco EL, Duarte-Franco E, Ferenczy A. Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection. CMAJ. 2001;164:1017-25.
5. Bosch FX, Castellsagué X, Muñoz N, De Sanjosé S, Ghaffari AM, González LC, et al. Male sexual behaviour and human papillomavirus DNA: key risk factors for cervical cancer in Spain. J Natl Cancer Inst. 1996;88:1060-7.
6. David T, Roberta R, Kuypers J, Kiviat N, Koetsawang A, Horda A, et al. Human papillomaviruses and cervical cancer in Bangkok. The role of husbands and commercial sex workers. Am J Epidemiology. 2001;153:740-8.
7. Castellsagué X, Bosch FX, Muñoz N, Meijer CJ, Shah KV, De Sanjosé S, et al. Male circumcision, penile human papillomavirus infection and cervical cancer in female partners. N Engl J Med. 2002;346:1105-12.
8. Castellsagué X, Bosch FX, Muñoz N. El papel del varón en el cancer cervical. Salud Pública Mex. 2003;45:S345-S53.
9. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervical papillomavirus infection in young women. N Engl J Med. 1998;338:423-8.
10. Muñoz N, Méndez F, Posso H, Molano M, Van den Brule A, Ronderos M, et al. Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis. 2004;190:2077-87.
11. De San José S, Valls I, Paz Cañadas M, Lloveras B, Quintana MJ, Shah KV, et al. Papiloma humano y de la inmunodeficiencia humana como factures de riesgo para el cáncer de cuello uterino en mujeres reclusas. Med Clin (Barc). 2000;115:81-4.
12. Vall Mayans M, De San José Llongueras S. El cancer de cuello uterino y la influencia del VIH en su desarrollo en mujeres jóvenes desfavorecidas socialmente. Med Clin (Barc). 2000;114:656-7.
13. Cardillo M, Hagan R, Abadi J, Abadi MA. CD4 T-cell count, viral load, and squamous intraepithelial lesions in women infected with the human immunodeficiency virus. Cancer. 2001;93:111-4.
14. Ahdieh L, Klein RS, Burk R, Cu-Uvin S, Schuman P, Duerr M, et al. Prevalence, incidence, and type specific persistence of human papillomavirus in human immunodeficiency virus (HIV) positive and HIV negative women. J Infect Dis. 2001;184:682-90.
15. Sun XW, Kuhn L, Ellerbrock TV, Chiasson MA, Bush TJ, Wright TC Jr. Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med. 1997;337:1343-9.
16. Koss LG. The Papanicolaou test for cervical cancer detection: a triumph and a tragedy. JAMA. 1989;261:737-43.
17. Dodd LG, Sneige N, Villarreal Y, Fanning CV, Staerkel GA, Carawa NP, et al. Quality assurance study of simultaneously sampled, non correlating cervical cytology and biopsies. Diagn Cytopathol. 1993;9:138-44.
18. Maiman M, Fruchter RG, Sedlis A, Feldman J, Chen P, Burk RD, et al. Prevalence, risk factors, and accuracy of cytologic screening for cervical intraepithelial neoplasia in women with the human immunodeficiency virus. Gynecol Oncol. 1998;68:233-9.
19. Fink JM, Fruchter RG, Maiman M, Kelly P, Sedlis A, Webber CA, et al. The adequacy of cytology and colposcopy in diagnosing cervical neoplasia in VIH seropositive women. Gynecol Oncol. 1994;55:133-7.
20. Bory JP, Cucherousset J, Lorenzato M, Gabriel R, Quereux C, Birembaut P, et al. Recurrent human papillomavirus infection detected with the hybrid capture II assay selects women with normal cervical smears at risk for developing high grade cervical lesions: a longitudinal study of 3091 women. Int J Cancer. 2002;102:519-25.
21. Lorincz A. Detección oportuna de cáncer cervical: nuevas alternatives y pautas de investigación. Salud Pública Mex. 2003;45:S376-87.
22. Schiffman M, Herrero R, Hildesheim A, Sherman ME, Bratti MC, Rodríguez AC, et al. HPV ADN testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA. 2000;283:87-93.
23. Muñoz N. Valor del test del virus del papiloma humano en el diagnóstico y cribado de la neoplasia cervical. Med Clin (Barc). 2003;121:455-6.
24. National Cancer Institute Workshop. The 1988 Bethesda System for reporting cervical/vaginal cytological diagnoses. JAMA. 1989;262:931-4.
25. Woodhouse SL, Stastny JF, Styer PE, Kenndet M, Praestgaard AH, Davey DD. Interobserver variability in subclassification of squamous intraepithelial lesions. Results of the college of American Pathologits interlaboratory comparison program in cervicovaginal cytology. Arch Pathol Lab Med. 1999;123:1079-84.
26. Fahet MT, Irwing L, Masaskill O. Meta analysis of Pap test accuracy. Am J Epidemiol. 1995;141:680-9.
27. Nanda K, McCroy DC, Myers E, Bastian LA, Hasselblad V, Mickey JD, et al. Accuracy of Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med. 2000;132:810-9.
28. Kinney WK, Manos MM, Hurley LB, Ransley JE. Where's the high-grade cervical neoplasia? The importance of the minimally abnormal Papanicolaou test. Obstet Gynecol. 1998;91:973-6.
29. Ordi J, Puig-Tintoré LM, Torné A, Sanz S, Esteve R, Romagosa C, et al. Contribución de la detección del virus del papiloma humano de alto riesgo al estudio de las lesiones premalignas y malignas del cervix uterino. Med Clin (Barc). 2003;121:441-5.
30. Cubie HA, Seagar AL, Beattie GJ, Monaghan S, Williams AR. A longitudinal study of HPV detection and cervical pathology in HIV infected women. Sex Transm Inf. 2000;76:257-61.
31. Burd E. Human papillomavirus and cervical cancer. Clin Microbiol Rev. 2003;16:1-17.
32. Minkoff H, Ahdieh L, Massad LS, Anastos K, Watts DH, Melnick S, et al. The effect of highly active antiretroviral therapy on cervical changes associated with oncogenetic HPV among VIH infected women. AIDS. 2001;15:2157-64.
33. Heard J, Tassie JM, Kazatchkine MD, Orth G. Highly active antiretroviral therapy enhances regression of cervical intraepithelial neoplasia in HIV seropositive women. AIDS. 2002;16:1799-802.
34. Palefsky JM. Cervical human papillomavirus infection and cervical intraepithelial neoplasia in women positive for human immunodeficiency virus in the era of highly active antiretroviral therapy. Curr Opin Oncol. 2003;15:382-8.
35. Uberti-Foppa C, Ferrari D, Lodini S, Reina S, Ameglio F, Grasso MA, et al. Long term of highly active antiretroviral therapy on cervical lesions in VIH positive women. AIDS. 2003;17:2136-8.
36. Branca M, Migliore G, Giulani M, Leoncini L, Hipólito G, Cappielo G, et al. Squamous intraepithelial lesions (SILs) and HPV associated changes in infected women or at risk of VIH. DIA-NAIDS Cooperative Study Group. Eur J Gynaecol Oncol. 2000;21:155-9.
37. Conti M, Agarossi A, Parazzini F, Mugigiasca ML, Boschini A, Negri E, et al. HPV, HIV infection, and risk of cervical intraepithelial neoplasia in former intravenous drug abusers. Gynecol Oncol. 1993;49:344-8.
38. Six C, Heard I, Bergeron C, Orth G, Poveda JD, Zagury P, et al. Comparative prevalence, incidence and short term prognosis of cervical squamous intraepithelial lesions amongst HIV positive and HIV negative women. AIDS. 1998;12:1047-56.
39. Sherman ME, Lorincz AT, Scott DR, Wacholder S, Castle PE, Glass AG, et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10 year cohort analysis. J Natl Cancer Inst. 2003;95:46-52.
40. Saslow D, Runowicz C, Solomon D, Moscicki AB, Smith R, Eyre H, et al. American Cancer Society Guideline for the early detection of cervical neoplasia and cancer. Cancer J Clin. 2002;52:342-62.
41. Nobbenhuis MA, Meijer CJ, Van den Breule AJ, Rozendaal FJ, Voorhoost EK, Risse EK, et al. Addition of high risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia. Br J Cancer. 2001;84:796-801.